Summary of Chengdu XianDao Conference Call Company Overview - Chengdu XianDao has diversified its global market presence, with the US market accounting for nearly 50% of revenue, strong growth in Europe, and domestic market revenue increasing to around 15% [2][4] - The company has over 600 formal clients and more than 2000 potential partners, including large multinational corporations and biotechnology firms [2][6] Financial Performance - In the first half of 2025, Chengdu XianDao's revenue grew by 17% year-on-year, with overseas market growth reaching 21% [3] - Net profit attributable to shareholders increased by nearly 400%, marking a historical high, while non-recurring net profit surged over 2000% [3] - The overall gross margin rose by 7 percentage points to 53%, with healthy margins across various technology sectors [11] Market and Client Structure - The company has seen a significant increase in domestic market revenue share from less than 5% to approximately 15% in recent quarters [4] - Emerging markets in Japan and South Korea are becoming more active, expected to account for 5% to 8% of revenue [4] Core Technology Platforms - Chengdu XianDao's four core technology platforms (L+SVD, OBT+TBD) have achieved over 40% growth, particularly in the molecular glue sector [2][7] - The Open Deal 5.0 initiative has received positive feedback from emerging biotech companies and academic institutions in the US [7] M&A and Synergy Effects - The acquisition of FBDD has begun to show synergy effects, with Welais achieving profitability in the first half of the year [8] - The company is actively seeking M&A opportunities to strengthen existing core businesses and explore new technologies [22] Future Growth and Development Plans - Chengdu XianDao plans to maintain stable growth in its main business over the next 3-5 years, focusing on custom library development and expanding nucleic acid synthesis and optimization services [5][16] - The company is also investing in the protein degradation field and building peptide libraries to meet growing market demand [17] Challenges and Innovations - The small nucleic acid field faces challenges in delivery systems, particularly in crossing barriers like the blood-brain barrier [18] - Chengdu XianDao is leveraging AI technology to optimize molecular screening and reduce the time from target identification to clinical candidates [19] Clinical Pipeline and Projects - The small molecule pipeline is progressing well, with project 146 for solid tumors entering Phase II clinical trials [15][33] - The company is also focusing on clinical projects in cardiovascular, metabolic, inflammation, and pain areas, with plans to submit new IND applications [32] Cost Management and Financial Outlook - R&D expenses are expected to remain around 15%, with management expenses decreasing by 5% year-on-year [26] - The company aims to reduce management expense ratios to industry median levels as revenue scales up [26] Conclusion - Chengdu XianDao is positioned for long-term growth through strategic market expansion, technological innovation, and a robust clinical pipeline, while actively managing costs and exploring M&A opportunities to enhance its competitive edge [39]

成都先导药物开发股份有限公司 2025 年"提质增效重回报"行动方案 半年度评估报告 为践行"以投资者为本"的发展理念，维护全体股东利益，促进公司高质量 发展，成都先导药物开发股份有限公司（以下简称"公司"或"成都先导"）积 极响应上海证券交易所关于开展科创板上市公司"提质增效重回报"专项行动的 倡议，结合自身战略目标及实际情况、宏观经济形势、行业发展趋势及市场需求 态势，于 2025 年 4 月推出"提质增效重回报"行动方案。2025 年上半年，行动 方案主要举措的进展及成效情况如下： 一、 成都先导发展现状 成都先导聚焦小分子及核酸新药的发现与优化，依托 DEL 技术（包括 DEL 库的设计、合成和筛选及拓展应用）、基于分子片段和三维结构信息的药物设计 （FBDD/SBDD）技术、基于寡核苷酸的药物研发平台（OBT）、靶向蛋白降解 平台相关技术（TPD）四大核心技术平台及公司其他关键新药研发能力（药物化 学、计算科学/AI、体外体内生物学评价、药物代谢学，分析化学，药学研究等）， 打造新药发现与优化的国际领先的研发体系，通过新药研发服务、不同阶段在研 项目转让及远期的药物上市，为医药工业输出不同阶段的新分 ...

1 成都先导药物开发股份有限公司 2025 年第一次临时股东大会会议资料 成都先导药物开发股份有限公司 2025 年第一次临时股东大会会议资料目录 成都先导药物开发股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 2025 年第一次临时股东大会会议资料 二〇二五年九月 | 2025 年第一次临时股东大会会议资料目录 2 | | --- | | 2025 年第一次临时股东大会会议须知 3 | | 2025 年第一次临时股东大会会议议程 6 | | 议案一：关于取消监事会、修订《成都先导药物开发股份有限公司章程》及其附 | | 件的议案 9 | | 议案二：关于修订及废止部分成都先导药物开发股份有限公司治理制度的议案.11 | | 议案三：关于公司《2025 年限制性股票激励计划（草案）》及其摘要的议案 12 | | 议案四：关于公司《2025 年限制性股票激励计划实施考核管理办法》的议案 13 | | 议案五：关于提请股东大会授权董事会办理公司 年限制性股票激励计划有关 2025 | | 事项的议案 14 | | 议案六：关于公司《2 ...

Core Insights - Chengdu XianDao reported a significant increase in revenue and profit for the first half of 2025, with operating income reaching 227 million yuan, a year-on-year growth of 16.58%, and net profit attributable to shareholders at 50.04 million yuan, up 390.72% [1] - The company focuses on becoming a leading innovative biopharmaceutical enterprise, emphasizing small molecule and nucleic acid drug discovery and optimization [1][2] - Chengdu XianDao has developed advanced technology platforms, including a DNA-encoded compound library (DEL), drug design based on molecular fragments and 3D structural information, oligonucleotide-based drug development (OBT), and targeted protein degradation (TPD) [1] Financial Performance - The company achieved a net cash flow from operating activities of 111 million yuan, reflecting a year-on-year increase of 51.48% [1] - The non-deductible net profit reached 53.91 million yuan, showing a remarkable growth of 2517.66% [1] Strategic Initiatives - Chengdu XianDao is actively leveraging market opportunities with a global perspective, enhancing cooperation, and optimizing international market strategies to improve operational efficiency [1] - The company is advancing its commercial projects and research initiatives across its technology platforms while exploring commercialization opportunities to achieve synchronized performance growth [1] - Structural adjustments in R&D investments have been made by the parent company and its UK subsidiary Vernalis, improving resource allocation efficiency while maintaining innovation capabilities [1] Future Outlook - The CEO emphasized the company's commitment to innovation-driven development and the creation of a new paradigm and ecosystem for drug research and development, aiming to generate greater and more sustainable value for shareholders, customers, and society [2]

Core Insights - Chengdu Xian Dao reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 227 million yuan, a year-on-year growth of 16.58%, and a net profit attributable to shareholders of 50.04 million yuan, up 390.72% [2][3] Financial Performance - The company achieved a net cash flow from operating activities of 111 million yuan, reflecting a year-on-year increase of 51.48% [2] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points compared to the previous year [2] Business Segments - The DEL segment, a cornerstone of Chengdu Xian Dao's business, generated revenue of 102 million yuan, marking a growth of 40.45% [3] - The UK subsidiary Vernalis confirmed milestone revenue, contributing to the steady development of the FBDD/SBDD platform [3] - The OBT segment expanded its traditional nucleoside monomer synthesis business while achieving commercial transformation of small nucleic acid one-stop projects [3] - The TPD segment actively explored new business models and initiated new project collaborations based on PROTAC technology [3] - The ChemSer segment saw a remarkable revenue increase of 94.17% due to the efficient operation of the automated high-throughput chemical synthesis platform [3] Market Strategy - The company is leveraging a global perspective to deepen collaborations and optimize international market strategies, enhancing operational efficiency and market positioning [3] - Chengdu Xian Dao is committed to advancing its technological platforms and research projects while exploring commercialization opportunities [3] Leadership Perspective - The CEO, Dr. Li Jin, emphasized the company's ongoing positive development and commitment to innovation-driven growth, aiming to create sustainable value for shareholders, clients, and society [4]

Core Viewpoint - Chengdu Xian Dao (688222) reported significant growth in revenue and profit for the first half of 2025, indicating a strong performance in the pharmaceutical R&D sector, particularly in small molecules and nucleic acid drugs [1][2]. Financial Performance - The company achieved operating revenue of 227 million yuan, a year-on-year increase of 16.58% [1] - Net profit reached 50.04 million yuan, up 390.72% year-on-year [1] - The net profit after deducting non-recurring items was 53.91 million yuan, reflecting a substantial increase of 2517.66% [1] - The net cash flow from operating activities was 111 million yuan, growing by 51.48% [1] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points year-on-year [1] Business Segments and Growth - Chengdu Xian Dao focuses on four core technology platforms: DEL technology, FBDD/SBDD, OBT, and TPD, which support its drug discovery and optimization capabilities [1][2] - The DEL segment, which includes the design, synthesis, and screening of DEL libraries, generated revenue of 102 million yuan, a year-on-year increase of 40.45% [2] - The OBT segment expanded its traditional nucleoside monomer synthesis business while achieving commercial transformation of small nucleic acid projects [3] - The TPD segment actively explored new business models and initiated new project collaborations based on PROTAC technology [3] Market Strategy and Resource Allocation - The company is leveraging domestic and international resources to optimize its market strategy and meet diverse customer demands [2] - Chengdu Xian Dao's UK subsidiary, Vernalis, confirmed milestone revenue during the reporting period, supporting the steady development of the FBDD/SBDD platform [2] - The company reported a 94.17% year-on-year increase in revenue from ChemSer services, driven by the efficient operation of its automated high-throughput chemical synthesis platform [3] - R&D investment increased year-on-year, while Vernalis adjusted its resource allocation to focus on commercial projects, resulting in a slight decrease in overall R&D expenses [3]

Core Viewpoint - Chengdu Xian Dao announced an incentive plan to grant 115 individuals a total of 1,052,200 restricted stocks, representing approximately 0.26% of the company's total share capital of about 401 million shares [1] Summary by Relevant Sections - **Incentive Plan Details** - The incentive plan involves granting restricted stocks to 115 individuals, sourced from shares repurchased in the secondary market or newly issued shares [1] - The total number of restricted stocks to be granted is 1,052,200 [1] - The grant price for the restricted stocks is set at 13.99 yuan per share [1] - **Stock Ownership and Conditions** - The restricted stocks represent about 0.26% of the company's total share capital at the time of the announcement [1] - The effective period for the restricted stocks is from the grant date until the stocks are fully vested or become invalid, with a maximum duration of 36 months [1]

Group 1 - The core viewpoint of the articles highlights Chengdu XianDao's strong performance in the first half of 2025, with significant growth in revenue, net profit, and gross margin [1][2] - Chengdu XianDao achieved an operating income of 227 million yuan, a year-on-year increase of 16.58% [1] - The net profit attributable to shareholders reached 50.042 million yuan, reflecting a remarkable year-on-year growth of 390.72% [1] - The net profit after deducting non-recurring gains and losses was 53.912 million yuan, showing a substantial increase of 2517.66% year-on-year [1] - The net cash flow from operating activities was 111 million yuan, up by 51.48% compared to the previous year [1] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points year-on-year [1] Group 2 - Chengdu XianDao is actively seizing market opportunities and enhancing cooperation with a global perspective, optimizing international market strategies [1] - The company has made structural adjustments to R&D investments to maintain innovation capabilities while improving resource allocation efficiency [1] - Chengdu XianDao has established an ESG work system based on international and domestic standards and published its first bilingual sustainability report [1] - The Chairman and CEO, Li Jin, emphasized the company's commitment to innovation-driven development and creating sustainable value for shareholders, customers, and society [2]

Core Viewpoint - The company is set to implement a restricted stock incentive plan for 2025, which has been reviewed and approved by the Board's Compensation and Assessment Committee, ensuring compliance with relevant laws and regulations [1][3]. Group 1: Compliance and Eligibility - The company does not have any circumstances that prohibit the implementation of the stock incentive plan as per the relevant laws and regulations [1]. - The identified incentive recipients meet all eligibility criteria and do not fall under any disqualifying conditions set by regulatory authorities [2][3]. Group 2: Plan Details and Approval Process - The drafting and review process of the incentive plan aligns with the requirements of the Company Law, Securities Law, and other relevant regulations, ensuring that the plan does not infringe on the interests of the company or its shareholders [3]. - The plan requires approval from the shareholders' meeting before implementation [3]. Group 3: Benefits and Mechanism - The implementation of the incentive plan is expected to enhance the company's incentive mechanism, improve the distribution system that combines incentives and constraints, and effectively boost the cohesion of the core team and the company's core competitiveness [3].

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]